

DAFTAR PUSTAKA

- Ahmad, B., Idrees, M., Ahmad, K., Bashir, S., & Jamil, S. (2017). *Molecular characterisation of isoniazid resistant clinical isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan*. 1224–1227. <https://pubmed.ncbi.nlm.nih.gov/28839308/>
- Allo, V. C. R. R., & Mursalim. (2020). *Uji Resistensi Primer Mycobacterium tuberculosis terhadap INH (Isonicotinyl hydrazide) pada Penderita Tuberkulosis*. 11, 56–61. <http://journal.poltekkes-mks.ac.id/ojs2/index.php/mediaanalisis/article/view/1517/1023>
- Bespyatykh, J., Shitikov, E., Guliaev, A., Smolyakov, A., Klimina, K., Veselovsky, V., Malakhova, M., Arapidi, G., Dogonadze, M., Manicheva, O., Bespiatykh, D., Mokrousov, I., Zhuravlev, V., Ilina, E., & Govorun, V. (2019). System OMICs analysis of Mycobacterium tuberculosis Beijing B0/W148 cluster. *Scientific Reports*, 9(1), 1–11. <https://doi.org/10.1038/s41598-019-55896-z>
- CDC. (2016). *National Action Plan for Combating Multidrug-Resistant Tuberculosis*. <https://www.cdc.gov/globalhivtb/images/usg-mdr-napreport-2016-final.pdf>
- Charan, A. S., Gupta, N., Ramakant Dixit, Piyush Arora, Patni, T., Antony, K., & Singh, M. (2020). Pattern of InhA and KatG mutations in isoniazid mono-resistant Mycobacterium tuberculosis isolates. *Lung India*, 35(1), 41–46. <https://doi.org/10.4103/lungindia.lungindia>
- Click, E. S., Kurbatova, E. V., Alexander, H., Dalton, T. L., Chen, M. P., Posey, J. E., Ershova, J., & Peter Cegielski, J. (2020). Isoniazid and Rifampin-Resistance Mutations Associated with Resistance to Second-Line Drugs and with Sputum Culture Conversion. *Journal of Infectious Diseases*, 221(12), 2072–2082. <https://doi.org/10.1093/infdis/jiaa042>
- Diandé, S., Ogbomon, E. O., Gueye, A., Diallo, A., Sawadogo, L. T., Nébié, B., Ouedraogo, F., Adama, M., Sawadogo, I., & Sangaré, L. (2019). Occurrence of mutations associated with rifampicin and isoniazid resistant in Mycobacterium tuberculosis isolates from patients in Burkina Faso. *International Journal of Molecular Biology*, 4(3), 106–111. <https://doi.org/10.15406/ijmboa.2019.04.00105>
- Ditjen P2P, K. R. (2020). *Dashboard Tuberkulosis Indonesia*. <https://tbindonesia.or.id/pustaka-tbc/dashboard-tb/>
- Eduardo, P., Da, A., & Palomino, J. C. (2011). *Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs*. *May*, 1417–1430. <https://doi.org/10.1093/jac/dkr173>
- Falzon, D., Jaramillo, E., Schünemann, H. J., Arentz, M., Bauer, M., Bayona, J., Blanc, L., Caminero, J. A., Daley, C. L., Duncombe, C., Fitzpatrick, C., Gebhard, A., Getahun, H., Henkens, M., Holtz, T. H., Keravec, J., Keshavjee, S., Khan, A. J., Kulier, R., ... Zignol, M. (2011). WHO

guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. *European Respiratory Journal*, 38(3), 516–528. <https://doi.org/10.1183/09031936.00073611>

- Fatchiyah, Arymingtyas, E. L., Widyarti, S., & Rahayu, S. (2011). *Biologi Molekuler Prinsip Dasar Analisis* (R. Astikawati (ed.)). Penerbit Erlangga.
- Heidary, F., Lashgarian, H. E., Karkhane, M., & Peerayeh, S. najar. (2020). Erratum: Molecular detection of isoniazid and rifampin resistance in mycobacterium tuberculosis isolates from Lorestan Province, Iran from 2014 to 2017 (*Arch Clin Infect Dis.*, (2020), 10.5812/archcid.81436). *Archives of Clinical Infectious Diseases*, 15(2), 1–6. <https://doi.org/10.5812/archcid.104069>
- Hsu, L. Y., Lai, L. Y., Hsieh, P. F., Lin, T. L., Lin, W. H., Tasi, H. Y., Lee, W. T., Jou, R., & Wang, J. T. (2020). Two Novel katG Mutations Conferring Isoniazid Resistance in Mycobacterium tuberculosis. *Frontiers in Microbiology*, 11(July). <https://doi.org/10.3389/fmicb.2020.01644>
- Huo, F., Lu, J., Zong, Z., Jing, W., Shi, J., Ma, Y., Dong, L., Zhao, L., Wang, Y., Huang, H., & Pang, Y. (2019). Change in prevalence and molecular characteristics of isoniazid-resistant tuberculosis over a 10-year period in China. *BMC Infectious Diseases*, 19(1), 1–7. <https://doi.org/10.1186/s12879-019-4333-4>
- Irianti, T., Kuswadi, Yasin, N. M., & Anggar, R. (2016). Anti-Tuberculosis. *Current Bioactive Compounds*, 212. <https://doi.org/10.2174/1573407210602010105>
- Isakova, J., Sovkhozova, N., Vinnikov, D., Goncharova, Z., Talaibekova, E., Aldasheva, N., & Aldashev, A. (2018). Mutations of rpoB, katG, inhA and ahp genes in rifampicin and isoniazid-resistant Mycobacterium tuberculosis in Kyrgyz Republic. *BMC Microbiology*, 18(1), 1–8. <https://doi.org/10.1186/s12866-018-1168-x>
- Kemenkes RI. (2012). *Modul Pelatihan Pemeriksaan Dahak Mikroskopis TB*.
- Kemenkes RI. (2017). Petunjuk Teknis Pemeriksaan TB Menggunakan Tes Cepat Molekuler. *Kementerian Kesehatan RI*, 6.
- PMK RI No. 67/2016: VI: B(2), Pub. L. No. B(2), (PMK RI No. 67/2016: VI: B(2)). (2016).
- Kurniawan, E., Diarti, M. W., & Pristianingrum, S. (2015). *Analisis Molekuler MDR-TB Dengan Teknik Sekuensing Dari Sampel Dahak Suspek Tb Di Nusa Tenggara Barat*. 1(1), 1436–1443.
- Kusdianingrum, D., Yustiantara, S., & Yowani, S. C. (2014). Amplifikasi dan Identifikasi Mutasi Regio Promotor inhA pada Isolat Mycobacterium tuberculosis Multidrug Resistance dengan Teknik Polymerase Chain Reaction. *Cakra Kimia*, 2(2), 37–41.
- Lempens, P., Meehan, C. J., Vandellanootte, K., Fissette, K., & Rijk, P. De. (2018).

Isoniazid resistance levels of *Mycobacterium tuberculosis* can largely be predicted by high- confidence resistance-conferring mutations. *Scientific Reports*, September 2017, 1–9. <https://doi.org/10.1038/s41598-018-21378-x>

- Liu, L., Jiang, F., Chen, L., Zhao, B., Dong, J., Sun, L., Zhu, Y., Liu, B., Zhou, Y., Yang, J., Zhao, Y., Jin, Q., & Zhang, X. (2018). The impact of combined gene mutations in *inhA* and *ahpC* genes on high levels of isoniazid resistance amongst *katG* non-315 in multidrug-resistant tuberculosis isolates from China. *Emerging Microbes and Infections*, 7(1). <https://doi.org/10.1038/s41426-018-0184-0>
- Machado, D., Perdigão, J., Ramos, J., Couto, I., Portugal, I., Ritter, C., Boettger, E. C., & Viveiros, M. (2013). High-level resistance to isoniazid and ethionamide in multidrug-resistant *Mycobacterium tuberculosis* of the Lisboa family is associated with *inhA* double mutations. *Journal of Antimicrobial Chemotherapy*, 68(8), 1728–1732. <https://doi.org/10.1093/jac/dkt090>
- Munir, A., Kumar, N., Ramalingam, S. B., Tamilzhalagan, S., Shanmugam, S. K., Palaniappan, A. N., Nair, D., Priyadarshini, P., Natarajan, M., Tripathy, S., Ranganathan, U. D., Peacock, S. J., Parkhill, J., Blundell, T. L., & Malhotra, S. (2019). Identification and Characterization of Genetic Determinants of Isoniazid and Rifampicin Resistance in *Mycobacterium tuberculosis* in Southern India. *Scientific Reports*, 9(1), 1–13. <https://doi.org/10.1038/s41598-019-46756-x>
- Narmandakh, E., Tumenbayar, O., Borolzoi, T., Erkhembayar, B., Boldoo, T., Dambaa, N., Burneebaatar, B., Nymadawa, N., Mitarai, S., Jav, S., Chiang, C., Oyuntuya, T., Tserelmaa, B., & Sarantuya, J. (2020). *Genetic Mutations Associated with Isoniazid Resistance in Mongolia*. 64(7), 1–7. https://www.researchgate.net/publication/340821971_Genetic_Mutations_Associated_with_Isoniazid_Resistance_in_Mycobacterium_tuberculosis_in_Mongolia
- Nurhayati, B., & Darmawati, S. (n.d.). *Biologi Sel dan Molekuler*. PPSDMK.
- Purkan, P., Ihsanawati, I., Natalia, D., Syah, Y. M., Retnoningrum, D. S., & Siswanto, I. (2018). Molecular Analysis of *katG* Encoding Catalase-Peroxidase from Clinical Isolate of Isoniazid-Resistant *Mycobacterium tuberculosis*. *Journal of Medicine and Life*, 11(2), 160–167. <https://pubmed.ncbi.nlm.nih.gov/30140323/>
- Purkan, Sri Puji Astuti Wahyuningsih, Retnowati, W., Amelia, D., & Alimny, A. N. (2015). *Structure - Activity Relationship of Mutant KatG from INH resistant Mycobacterium tuberculosis*. 1–27. <http://repository.unair.ac.id/86475/> pada 28 Januari 2021
- Ravi, I., Baunthiyal, M., & Saxena, J. (2014). *Advances in Biotechnology* (Issue October 2013).
- Sakamoto, K. (2012). *The Pathology of Mycobacterium tuberculosis Infection*.

- Sarwani Dewi, D. S., Nurlaela, S., & A, I. Z. (2012). Faktor Risiko Multidrug Resistant Tuberculosis (MDR-TB). *Jurnal Kesehatan Masyarakat*, 8(1), 60–66.
- Seifert, M., Catanzaro, D., Catanzaro, A., & Rodwell, T. C. (2015). Genetic mutations associated with isoniazid resistance in *Mycobacterium tuberculosis*: A systematic review. *PLoS ONE*, 10(3), 1–13. <https://doi.org/10.1371/journal.pone.0119628>
- Siregar, M. I. T. (2015). Mekanisme Resistensi Isoniazid & Mutasi Gen KatG Ser315Thr (G944C) *Mycobacterium tuberculosis* Sebagai Penyebab Tersering Resistensi Isoniazid. *Jambi Medical Journal*, 3(2), 119–131. <https://media.neliti.com/media/publications/70487-ID-mekanisme-resistensi-isoniazid-mutasi-ge.pdf>
- Smith, T., Wolff, K. A., & Nguyen, L. (2013). Molecular biology of drug resistance in *Mycobacterium tuberculosis*. *Current Topics in Microbiology and Immunology*. <https://doi.org/10.1007/82-2012-279>
- Stackebrandt, E., Smida, J., & Kazda, J. (1997). *Adaptation of Mycobacterium smegmatis to Stationary phase*.
- Tseng, S., Tai, C., Li, C., & Lin, C. (2013). ScienceDirect The mutations of katG and inhA genes of isoniazid-resistant *Mycobacterium tuberculosis* isolates in Taiwan. *Journal of Microbiology, Immunology and Infection*, 48(3), 249–255. <https://doi.org/10.1016/j.jmii.2013.08.018>
- Vila-Viçosa, D., Victor, B. L., Ramos, J., Machado, D., Viveiros, M., Switala, J., Loewen, P. C., Leitao, R., Martins, F., & Machuqueiro, M. (2017). Insights on the Mechanism of Action of INH-C10 as an Antitubercular Prodrug. *Molecular Pharmaceutics*. <https://doi.org/10.1021/acs.molpharmaceut.7b00719>
- Vilchèze, C., & Jr, W. R. J. (2019). *The Isoniazid Paradigm of Killing, Resistance, and Persistence in Mycobacterium tuberculosis*. 431(18), 3450–3461. <https://doi.org/10.1016/j.jmb.2019.02.016>.The
- Warmadewi, D. A. (2017). Buku Ajar Mutasi Genetik. *Mutasi Genetik*, 15–16(Mutasi), 1–53.
- WHO. (2020). *Global Tuberculosis Report 2020*. <https://www.who.int/publications/i/item/9789240013131>